Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 2Active not recruiting 1

Sponsor Class

INDUSTRY 13OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Hepatocellular 19Neoplasm Metastasis 13Melanoma 12Nasopharyngeal Carcinoma 10Carcinoma, Non-Small-Cell Lung 10Stomach Neoplasms 8Rectal Neoplasms 8Pancreatic Neoplasms 8Colorectal Neoplasms 8Squamous Cell Carcinoma of Head and Neck 6Neoplasms 6Locally Advanced Rectal Cancer 6Carcinoma, Renal Cell 6Uterine Cervical Neoplasms 4Recurrence 4Lymphoma, Extranodal NK-T-Cell 4Triple Negative Breast Neoplasms 3Sarcoma 3Nasopharyngeal Neoplasms 3Glioblastoma 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Cholangiocarcinoma 3Thyroid Neoplasms 2Solid Tumor 2Prostatic Neoplasms 2Lymphoma 2Lung Neoplasms 2Kidney Neoplasms 2Gastrointestinal Stromal Tumors 2

Interventions

Carboplatin 88pembrolizumab 85Paclitaxel 71Cyclophosphamide 63Capecitabine 38Doxorubicin 37Taxes 29130-nm albumin-bound paclitaxel 29Cisplatin 25Albumin-Bound Paclitaxel 22Epirubicin 21Drug Therapy 21Docetaxel 20sacituzumab govitecan 19olaparib 19camrelizumab 18atezolizumab 18Gemcitabine 17eribulin 16durvalumab 16Bevacizumab 16Radiotherapy 15toripalimab 14Specimen Handling 14Biopsy 13Everolimus 12Magnetic Resonance Spectroscopy 11apatinib 10Nivolumab 10talazoparib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Triple Negative Breast Neoplasms × spartalizumab × Clear all
NCT04802876 2025-03-21

ACROPOLI

SOLTI Breast Cancer Research Group

Phase 2 Active not recruiting
184 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05556200 2023-04-12

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Unknown
58 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05402722 2022-06-02

Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

Beijing 302 Hospital

Phase 2 Unknown
30 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡